Angelo M. De Marzo - Publications

Affiliations: 
Johns Hopkins University, Baltimore, MD 
Area:
Molecular Biology, Cell Biology, Medicine and Surgery, Oncology

274 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Bergom HE, Sena LA, Day A, Miller B, Miller CD, Lozada JR, Zorko N, Wang J, Shenderov E, Lobo FP, Caramella-Pereira F, Marchionni L, Drake CG, Lotan T, De Marzo AM, et al. Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer. Npj Genomic Medicine. 9: 7. PMID 38253539 DOI: 10.1038/s41525-024-00392-1  0.356
2024 Markowski MC, Taplin ME, Aggarwal R, Sena LA, Wang H, Qi H, Lalji A, Sinibaldi V, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Sanin DE, Yegnasubramanian S, Gomes-Alexandre C, ... ... De Marzo AM, et al. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nature Communications. 15: 14. PMID 38167882 DOI: 10.1038/s41467-023-44514-2  0.375
2023 Dairo OO, DePaula Oliveira L, Schaffer E, Vidotto T, Mendes AAA, Lu J, Huynh SV, Hicks JL, Sowalsky AG, De Marzo AM, Joshu CE, Hanratty B, Sfanos KS, Isaacs WB, Haffner MC, et al. FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-Genomic Features of Prostate Cancer. Cancer Research Communications. PMID 38112617 DOI: 10.1158/2767-9764.CRC-23-0248  0.582
2023 Wang F, Liu C, Vidal I, Mana-Ay M, Voter AF, Solnes LB, Ross AE, Gafita A, Schaeffer EM, Bivalacqua TJ, Pienta KJ, Pomper MG, Lodge MA, Song DY, Oldan JD, ... ... De Marzo AM, et al. Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted F-DCFPyL PET/CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 38050147 DOI: 10.2967/jnumed.123.266005  0.321
2023 Chen J, Zheng Q, Hicks JL, Trabzonlu L, Ozbek B, Jones T, Vaghasia AM, Larman TC, Wang R, Markowski MC, Denmeade SR, Pienta KJ, Hruban RH, Antonarakis ES, Gupta A, ... ... De Marzo AM, et al. MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. Jci Insight. PMID 37971875 DOI: 10.1172/jci.insight.169868  0.631
2023 Mori JO, Elhussin I, Brennen WN, Graham MK, Lotan TL, Yates CC, De Marzo AM, Denmeade SR, Yegnasubramanian S, Nelson WG, Denis GV, Platz EA, Meeker AK, Heaphy CM. Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nature Reviews. Urology. PMID 37907729 DOI: 10.1038/s41585-023-00827-x  0.667
2023 Graham MK, Wang R, Chikarmane R, Wodu B, Vaghasia A, Gupta A, Zheng Q, Hicks J, Sysa-Shah P, Pan X, Castagna N, Liu J, Meyers J, Skaist A, Zhang Y, ... ... De Marzo AM, et al. Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. Biorxiv : the Preprint Server For Biology. PMID 37905029 DOI: 10.1101/2023.09.07.553268  0.67
2023 Patel RA, Sayar E, Coleman I, Roudier MP, Hanratty B, Low JY, Jaiswal N, Ajkunic A, Dumpit R, Ercan C, Salama N, O'Brien VP, Isaacs WB, Epstein JI, De Marzo AM, et al. Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer. The Journal of Pathology. PMID 37850574 DOI: 10.1002/path.6216  0.687
2023 Huang FW, Song H, Weinstein HN, Xie J, Cooperberg MR, Hicks J, Mummert L, De Marzo AM, Sfanos KS. Club-like cells in proliferative inflammatory atrophy of the prostate. The Journal of Pathology. 261: 85-95. PMID 37550827 DOI: 10.1002/path.6149  0.58
2023 Gupta H, Inoue H, Nakai Y, Nakayama M, Jones T, Hicks JL, Kumar B, Gurel M, Nelson WG, De Marzo AM, Yegnasubramanian S. Progressive spreading of DNA methylation in the GSTP1 promoter CpG island across transitions from precursors to invasive prostate cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 37347938 DOI: 10.1158/1940-6207.CAPR-22-0485  0.31
2023 Erak E, Oliveira LD, Mendes AA, Dairo O, Ertunc O, Kulac I, Baena-Del Valle JA, Jones T, Hicks JL, Glavaris S, Guner G, Vidal ID, Markowski M, de la Calle C, Trock BJ, ... ... De Marzo AM, et al. Predicting Prostate Cancer Molecular Subtype with Deep Learning on Histopathologic Images. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 100247. PMID 37307876 DOI: 10.1016/j.modpat.2023.100247  0.37
2023 Ertunc O, Smearman E, Zheng Q, Hicks JL, Brosnan-Cashman JA, Jones T, Gomes-Alexandre C, Trabzonlu L, Meeker AK, De Marzo AM, Heaphy CM. Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate. Biorxiv : the Preprint Server For Biology. PMID 37066381 DOI: 10.1101/2023.04.04.535575  0.365
2023 Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, Ji H, Allaf ME, Chapman C, Moore PA, Chen F, Sorg K, White AM, Church SE, Hudson B, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nature Medicine. PMID 37012549 DOI: 10.1038/s41591-023-02284-w  0.464
2023 Chen J, Zheng Q, Hicks JL, Trabzonlu L, Ozbek B, Jones T, Vaghasia A, Larman TC, Wang R, Markowski MC, Denmeade SR, Pienta KJ, Hruban RH, Antonaraskis ES, Gupta A, ... ... De Marzo AM, et al. MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. Biorxiv : the Preprint Server For Biology. PMID 36865273 DOI: 10.1101/2023.02.20.529259  0.63
2022 Graham MK, Chikarmane R, Wang R, Vaghasia A, Gupta A, Zheng Q, Wodu B, Pan X, Castagna N, Liu J, Meyers J, Skaist A, Wheelan S, Simons BW, Bieberich C, ... ... De Marzo AM, et al. Single-cell atlas of epithelial and stromal cell heterogeneity by lobe and strain in the mouse prostate. The Prostate. PMID 36373171 DOI: 10.1002/pros.24460  0.501
2022 Trabzonlu L, Pienta KJ, Trock BJ, De Marzo AM, Amend SR. Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer. The Prostate. PMID 36372998 DOI: 10.1002/pros.24459  0.555
2022 Patel RA, Coleman I, Roudier MP, Konnick EQ, Hanratty B, Dumpit R, Lucas JM, Ang LS, Low JY, Tretiakova MS, Ha G, Lee JK, True LD, De Marzo AM, Nelson PS, et al. Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations. Cancer Research Communications. 2: 277-285. PMID 36337169 DOI: 10.1158/2767-9764.crc-21-0156  0.694
2022 Low JY, Ko M, Hanratty B, Patel RA, Bhamidipati A, Heaphy CM, Sayar E, Lee JK, Li S, De Marzo AM, Nelson WG, Gupta A, Yegnasubramanian S, Ha G, Epstein JI, et al. Genomic Characterization of Prostatic Basal Cell Carcinoma. The American Journal of Pathology. PMID 36309102 DOI: 10.1016/j.ajpath.2022.09.010  0.589
2022 Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, ... ... De Marzo AM, et al. Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. The Journal of Clinical Investigation. PMID 36194476 DOI: 10.1172/JCI162396  0.628
2022 Trock BJ, Jing Y, Mabey B, Sangale Z, Lenz L, Haney N, Vidal I, Glavaris SA, Guner G, Ertunc O, Kulac I, Baena Del Valle JA, Jones T, Han M, Partin AW, ... ... De Marzo AM, et al. Cell Cycle Progression Score, But Not PTEN Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-Risk Prostate Cancer in Men Treated with and without Salvage Radiotherapy. The Journal of Urology. 101097JU000000000000. PMID 36006048 DOI: 10.1097/JU.0000000000002922  0.59
2022 Maynard JP, Godwin TN, Lu J, Vidal I, Lotan TL, De Marzo AM, Joshu CE, Sfanos KS. Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities. The Prostate. PMID 35971807 DOI: 10.1002/pros.24424  0.558
2022 Heaphy CM, Joshu CE, Barber JR, Davis C, Lu J, Zarinshenas R, Giovannucci E, Mucci LA, Stampfer MJ, Han M, De Marzo AM, Lotan TL, Platz EA, Meeker AK. The prostate tissue-based telomere biomarker as a prognostic tool for metastasis and death from prostate cancer after prostatectomy. The Journal of Pathology. Clinical Research. PMID 35836303 DOI: 10.1002/cjp2.288  0.63
2022 Pinckaers H, van Ipenburg J, Melamed J, De Marzo A, Platz EA, van Ginneken B, van der Laak J, Litjens G. Predicting biochemical recurrence of prostate cancer with artificial intelligence. Communications Medicine. 2: 64. PMID 35693032 DOI: 10.1038/s43856-022-00126-3  0.633
2022 Markowski MC, Wang H, De Marzo AM, Schweizer MT, Antonarakis ES, Denmeade SR. Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. European Urology Open Science. 41: 112-115. PMID 35677016 DOI: 10.1016/j.euros.2022.05.006  0.574
2022 Peiffer LB, Hicks J, Sosa RY, De Marzo AM, Sfanos KS, Maynard JP. Modeling Human Prostate Cancer Metastasis in Mice Resection of Subcutaneous Allografts. Frontiers in Oncology. 12: 877536. PMID 35574356 DOI: 10.3389/fonc.2022.877536  0.482
2022 Ye F, Han X, Shao Y, Lo J, Zhang F, Wang J, Melamed J, Deng FM, Sfanos KS, De Marzo A, Ren G, Wang D, Zhang D, Lee P. Identification of novel biomarkers differentially expressed between African-American and Caucasian-American prostate cancer patients. American Journal of Cancer Research. 12: 1660-1670. PMID 35530298  0.356
2022 Mendes AA, Lu J, Kaur HB, Zheng SL, Xu J, Hicks J, Weiner AB, Schaeffer EM, Ross AE, Balk SP, Taplin ME, Lack NA, Tekoglu E, Maynard JP, De Marzo AM, et al. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer. PMID 35333400 DOI: 10.1002/cncr.34190  0.314
2022 Ozbek B, Ertunc O, Erickson A, Vidal ID, Gomes-Alexandre C, Guner G, Hicks JL, Jones T, Taube JM, Sfanos KS, Yegnasubramanian S, De Marzo AM. Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer. The Prostate. PMID 35188986 DOI: 10.1002/pros.24315  0.56
2022 Ruder S, Gao Y, Ding Y, Bu P, Miles B, De Marzo A, Wheeler T, McKenney JK, Auman H, Fazli L, Simko J, Coll AH, Troyer DA, Carroll PR, Gleave M, et al. Development and Validation of a Quantitative Reactive Stroma Biomarker (qRS) for Prostate Cancer Prognosis. Human Pathology. PMID 35176252 DOI: 10.1016/j.humpath.2022.01.009  0.565
2022 de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EA, De Marzo AM, Mu P, Coloff JL, et al. Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 41: 1234. PMID 35145235 DOI: 10.1038/s41388-022-02228-7  0.619
2022 Ouellet V, Erickson A, Wiley K, Morrissey C, Berge V, Moreno CS, Tasken KA, Trudel D, True LD, Lewis MS, Svindland A, Ertunc O, Vidal ID, Osunkoya AO, Jones T, ... ... De Marzo AM, et al. The Movember Global Action Plan 1 (GAP1) - Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35131885 DOI: 10.1158/1055-9965.EPI-21-0600  0.568
2022 Nelson WG, Brawley OW, Isaacs WB, Platz EA, Yegnasubramanian S, Sfanos KS, Lotan TL, De Marzo AM. Health inequity drives disease biology to create disparities in prostate cancer outcomes. The Journal of Clinical Investigation. 132. PMID 35104804 DOI: 10.1172/JCI155031  0.632
2022 de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EE, De Marzo AM, Mu P, Coloff JL, et al. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. PMID 35067686 DOI: 10.1038/s41388-021-02157-x  0.663
2021 Lopez-Bujanda ZA, Haffner MC, Chaimowitz MG, Chowdhury N, Venturini NJ, Patel RA, Obradovic A, Hansen CS, Jacków J, Maynard JP, Sfanos KS, Abate-Shen C, Bieberich CJ, Hurley PJ, Selby MJ, ... ... De Marzo AM, et al. Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. Nature Cancer. 2: 803-818. PMID 35122025 DOI: 10.1038/s43018-021-00227-3  0.477
2021 Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa RY, Peiffer LB, Joshu CE, Lotan TL, De Marzo AM, Sfanos KS. P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. The Journal of Pathology. PMID 34652816 DOI: 10.1002/path.5815  0.609
2021 Kumar R, Mendonca J, Owoyemi O, Boyapati K, Thomas N, Kanacharoen S, Coffey M, Topiwala D, Gomes C, Ozbek B, Jones T, Rosen M, Dong L, Wiens S, Brennen WN, ... ... De Marzo AM, et al. Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer. Cancer Research. PMID 34645612 DOI: 10.1158/0008-5472.CAN-20-3607  0.407
2021 Markowski MC, Kachhap S, De Marzo AM, Sena LA, Luo J, Denmeade SR, Antonarakis ES. Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. Clinical Genitourinary Cancer. PMID 34538582 DOI: 10.1016/j.clgc.2021.08.001  0.517
2021 Asrani K, Torres AFC, Woo J, Vidotto T, Tsai HK, Luo J, Corey E, Hanratty B, Coleman I, Yegnasubramanian S, De Marzo AM, Nelson PS, Haffner MC, Lotan TL. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer. The Journal of Pathology. PMID 34431104 DOI: 10.1002/path.5781  0.615
2021 Haffner MC, Bhamidipati A, Tsai HK, Esopi DM, Vaghasia AM, Low JY, Patel RA, Guner G, Pham MT, Castagna N, Hicks J, Wyhs N, Aebersold R, De Marzo AM, Nelson WG, et al. Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer. The Prostate. PMID 34402095 DOI: 10.1002/pros.24210  0.587
2021 Shrestha E, Coulter JB, Guzman W, Ozbek B, Hess MM, Mummert L, Ernst SE, Maynard JP, Meeker AK, Heaphy CM, Haffner MC, De Marzo AM, Sfanos KS. Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34341114 DOI: 10.1073/pnas.2018976118  0.642
2021 Vidal I, Zheng Q, Hicks JL, Chen J, Platz EA, Trock BJ, Kulac I, Baena-Del Valle JA, Sfanos KS, Ernst S, Jones T, Maynard JP, Glavaris SA, Nelson WG, Yegnasubramanian S, ... De Marzo AM, et al. GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. Plos One. 16: e0241934. PMID 34191807 DOI: 10.1371/journal.pone.0241934  0.584
2021 Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33958727 DOI: 10.1038/s41388-021-01805-6  0.492
2021 de Groot AE, Myers KV, Krueger TEG, Kiemen AL, Nagy NH, Brame A, Torres VE, Zhang Z, Trabzonlu L, Brennen WN, Wirtz D, De Marzo AM, Amend SR, Pienta KJ. Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models. The Prostate. PMID 33949714 DOI: 10.1002/pros.24139  0.575
2021 Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. Jci Insight. PMID 33724955 DOI: 10.1172/jci.insight.146827  0.559
2021 Severson TM, Zhu Y, De Marzo AM, Jones T, Simons JW, Nelson WG, Yegnasubramanian S, Freedman ML, Wessels L, Bergman AM, Haffner MC, Zwart W. Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases. Molecular Oncology. PMID 33576154 DOI: 10.1002/1878-0261.12923  0.647
2021 Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33564077 DOI: 10.1038/s41388-021-01640-9  0.492
2021 Langston ME, Sfanos KS, Khan S, Nguyen TQ, De Marzo AM, Platz EA, Sutcliffe S. Why Do Epidemiologic Studies Find an Inverse Association Between Intraprostatic Inflammation and Prostate Cancer: A Possible Role for Colliding Bias? Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 30: 255-259. PMID 33547143 DOI: 10.1158/1055-9965.EPI-20-1009  0.663
2021 Chadid S, Song X, Schenk JM, Gurel B, Lucia MS, Thompson IM, Neuhouser ML, Goodman PJ, Parnes HL, Lippman SM, Nelson WG, De Marzo AM, Platz EA. Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. Nutrition and Cancer. 1-8. PMID 33511883 DOI: 10.1080/01635581.2021.1879879  0.548
2020 Arriaga JM, Panja S, Alshalalfa M, Zhao J, Zou M, Giacobbe A, Madubata CJ, Yeji Kim J, Rodriguez A, Coleman I, Virk RK, Hibshoosh H, Ertunc O, Ozbek B, Fountain J, ... ... De Marzo AM, et al. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nature Cancer. 1: 1082-1096. PMID 34085047 DOI: 10.1038/s43018-020-00125-0  0.557
2020 Joshu CE, Heaphy CM, Barber JR, Lu J, Zarinshenas R, Davis C, Han M, Lotan TL, Sfanos KS, De Marzo AM, Meeker AK, Platz EA. Obesity is associated with shorter telomere length in prostate stromal cells in men with aggressive prostate cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 33355185 DOI: 10.1158/1940-6207.CAPR-20-0250  0.457
2020 Hempel Sullivan H, Maynard JP, Heaphy CM, Lu J, De Marzo AM, Lotan TL, Joshu CE, Sfanos KS. Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes. The Journal of Pathology. PMID 33338262 DOI: 10.1002/path.5606  0.46
2020 Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Genomic and phenotypic heterogeneity in prostate cancer. Nature Reviews. Urology. PMID 33328650 DOI: 10.1038/s41585-020-00400-w  0.667
2020 Guccini I, Revandkar A, D'Ambrosio M, Colucci M, Pasquini E, Mosole S, Troiani M, Brina D, Sheibani-Tezerji R, Elia AR, Rinaldi A, Pernigoni N, Rüschoff JH, Dettwiler S, De Marzo AM, et al. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis. Cancer Cell. PMID 33186519 DOI: 10.1016/j.ccell.2020.10.012  0.635
2020 Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, et al. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 4. PMID 33015525 DOI: 10.1200/PO.20.00097  0.633
2020 Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 32989253 DOI: 10.1038/s41388-020-01479-6  0.357
2020 Kaur H, Salles DC, Murali S, Hicks JL, Nguyen M, Pritchard CC, De Marzo AM, Lanchbury JS, Trock BJ, Isaacs WB, Timms KM, Antonarakis ES, Lotan TL. Genomic and Clinical-Pathologic Characterization of -deficient Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32694154 DOI: 10.1158/1078-0432.Ccr-20-0764  0.649
2020 Hurwitz LM, Kulac I, Gumuskaya B, Baena Del Valle JA, Benedetti I, Pan F, Liu JO, Marrone MT, Arnold KB, Goodman PJ, Tangen CM, Lucia MS, Thompson IM, Drake CG, Isaacs WB, ... ... De Marzo AM, et al. Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prevention Research (Philadelphia, Pa.). PMID 32581009 DOI: 10.1158/1940-6207.Capr-19-0450  0.53
2020 de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, Gil J, Drake CG, Alimonti A. Prostate carcinogenesis: inflammatory storms. Nature Reviews. Cancer. PMID 32546840 DOI: 10.1038/S41568-020-0267-9  0.593
2020 Chadid S, Barber JR, Nelson WG, Gurel B, Lucia MS, Thompson IM, Goodman PJ, Stanczyk FZ, Parnes HL, Lippman SM, De Marzo AM, Platz EA. The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial. The Prostate. PMID 32506665 DOI: 10.1002/Pros.24023  0.592
2020 Esopi D, Graham MK, Brosnan-Cashman JA, Meyers J, Vaghasia A, Gupta A, Kumar B, Haffner MC, Heaphy CM, De Marzo AM, Meeker AK, Nelson WG, Wheelan SJ, Yegnasubramanian S. Pervasive promoter hypermethylation of silenced TERT alleles in human cancers. Cellular Oncology (Dordrecht). PMID 32468444 DOI: 10.1007/S13402-020-00531-7  0.307
2020 Heaphy CM, Haffner MC, Graham MK, Lim D, Davis C, Corey E, Epstein JI, Eisenberger MA, Wang H, De Marzo AM, Meeker AK, Lotan TL. Telomere lengths differ significantly between small cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. Human Pathology. PMID 32389660 DOI: 10.1016/J.Humpath.2020.04.014  0.607
2020 Obradovic AZ, Dallos M, Zahurak ML, Partin AW, Schaeffer EM, Ross AE, Allaf ME, Nirschl TR, Chapman CG, O'Neal T, Cao H, Durham JN, Guner G, Baena-Del Valle JA, Ertunc O, ... De Marzo AM, et al. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32173650 DOI: 10.1158/1078-0432.Ccr-19-3372  0.533
2020 Hempel Sullivan H, Heaphy CM, Kulac I, Cuka N, Lu J, Barber JR, De Marzo AM, Lotan TL, Joshu CE, Sfanos KS. High Extra-tumoral Mast Cell Counts are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 31932412 DOI: 10.1158/1055-9965.Epi-19-0962  0.349
2020 Heaphy CM, Joshu CE, Barber JR, Davis C, Zarinshenas R, De Marzo AM, Lotan TL, Sfanos KS, Meeker AK, Platz EA. Racial difference in prostate cancer cell telomere lengths in men with higher-grade prostate cancer: a clue to the racial disparity in prostate cancer outcomes. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 31915143 DOI: 10.1158/1055-9965.Epi-19-1462  0.629
2019 Graham MK, Kim J, Da J, Brosnan-Cashman JA, Rizzo A, Baena Del Valle JA, Chia L, Rubenstein M, Davis C, Zheng Q, Cope L, Considine M, Haffner MC, De Marzo AM, Meeker AK, et al. Functional loss of ATRX and TERC activates Alternative Lengthening of Telomeres (ALT) in LAPC4 prostate cancer cells. Molecular Cancer Research : McR. PMID 31611308 DOI: 10.1158/1541-7786.Mcr-19-0654  0.576
2019 Maynard JP, Ertunc O, Kulac I, Baena Del Valle JA, De Marzo AM, Sfanos KS. Interleukin-8 Expression is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer. Molecular Cancer Research : McR. PMID 31604846 DOI: 10.1158/1541-7786.Mcr-19-0595  0.328
2019 Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, Giunchi F, Platz EA, De Marzo AM, Mucci LA, Fiorentino M, Ebot EM. A prospective study of intraprostatic inflammation, focal atrophy, and progression to lethal prostate cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 31533941 DOI: 10.1158/1055-9965.Epi-19-0713  0.615
2019 Low JY, Sirajuddin P, Moubarek M, Agarwal S, Rege A, Guner G, Liu H, Yang Z, De Marzo AM, Bieberich C, Laiho M. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer. The Prostate. PMID 31524299 DOI: 10.1002/Pros.23909  0.535
2019 Porter CM, Haffner MC, Kulac I, Maynard JP, Baena-Del Valle JA, Isaacs WB, Yegnasubramanian S, De Marzo AM, Sfanos KS. Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis. The American Journal of Pathology. PMID 31499027 DOI: 10.1016/J.Ajpath.2019.07.016  0.592
2019 Amend SR, Torga G, Lin KC, Kostecka LG, de Marzo A, Austin RH, Pienta KJ. Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance. The Prostate. PMID 31376205 DOI: 10.1002/Pros.23877  0.362
2019 Langston ME, Bhalla A, Alderete JF, Nevin RL, Pakpahan R, Hansen J, Elliott D, De Marzo AM, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Zenilman JM, Platz EA, Sutcliffe S. Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk. The Prostate. PMID 31376187 DOI: 10.1002/Pros.23886  0.608
2019 Zarif JC, Baena-Del Valle JA, Hicks JL, Heaphy CM, Vidal I, Luo J, Lotan TL, Hooper JE, Isaacs WB, Pienta KJ, De Marzo AM. Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. European Urology Oncology. 2: 429-436. PMID 31277779 DOI: 10.1016/J.Euo.2018.09.014  0.501
2019 Wang A, Barber JR, Tin A, De Marzo AM, Kottgen A, Joshu CE, Platz EA. Serum Urate, Genetic Variation, and Prostate Cancer Risk: Atherosclerosis Risk in Communities (ARIC) Study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 28: 1259-1261. PMID 31263056 DOI: 10.1158/1055-9965.Epi-19-0161  0.614
2019 Peiffer LB, Poynton SL, Ernst SE, Hicks JL, De Marzo AM, Sfanos KS. Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis. The Prostate. PMID 31212384 DOI: 10.1002/Pros.23841  0.541
2019 Srivastava S, Koay EJ, Borowsky AD, De Marzo AM, Ghosh S, Wagner PD, Kramer BS. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nature Reviews. Cancer. PMID 31024081 DOI: 10.1038/S41568-019-0142-8  0.356
2019 Hao L, Thomas S, Greer T, Vezina CM, Bajpai S, Ashok A, De Marzo AM, Bieberich C, Li L, Ricke WA. Quantitative proteomic analysis of a genetically induced prostate inflammation mouse model via custom 4-plex DiLeu isobaric labeling. American Journal of Physiology. Renal Physiology. PMID 30995113 DOI: 10.1152/Ajprenal.00387.2018  0.558
2019 Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC, Lotan TL. Intraductal Carcinoma of the Prostate in the Absence of High Grade Invasive Carcinoma Represents a Molecularly Distinct Type of in situ Carcinoma Enriched with Oncogenic Driver Mutations. The Journal of Pathology. PMID 30993692 DOI: 10.1002/Path.5283  0.316
2019 Ashok A, Keener RA, Rubenstein M, Stookey S, Bajpai S, Hicks J, Alme AK, Drake CG, Zheng Q, Trabzonlu L, Yegnasubramanian S, De Marzo AM, Bieberich CJ. Consequences of interleukin 1β-triggered chronic inflammation in the mouse prostate gland: Altered architecture associated with prolonged CD4 infiltration mimics human proliferative inflammatory atrophy. The Prostate. PMID 30900284 DOI: 10.1002/Pros.23784  0.503
2019 Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Translational Medicine. PMID 30735000 DOI: 10.1002/Sctm.18-0230  0.351
2018 Marrone MT, Joshu CE, Peskoe SB, De Marzo AM, Heaphy CM, Lupold SE, Meeker AK, Platz EA. Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis. Clinical Chemistry. PMID 30518666 DOI: 10.1373/Clinchem.2018.293365  0.486
2018 Yu SH, Maynard JP, Vaghasia AM, De Marzo AM, Drake CG, Sfanos KS. A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth. The Prostate. PMID 30345534 DOI: 10.1002/Pros.23726  0.487
2018 Guedes LB, Morais CL, Fedor H, Hicks J, Gurel B, Melamed J, Lee P, Gopalan A, Knudsen BS, True LD, Scher HI, Fine SW, Trock BJ, De Marzo AM, et al. Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Archives of Pathology & Laboratory Medicine. PMID 30295067 DOI: 10.5858/Arpa.2018-0068-Oa  0.654
2018 Axelrod HD, Valkenburg KC, Amend SR, Hicks JL, Parsana P, Torga G, De Marzo AM, Pienta KJ. AXL is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Molecular Cancer Research : McR. PMID 30291220 DOI: 10.1158/1541-7786.MCR-18-0718  0.552
2018 Tosoian JJ, Guedes LB, Morais CL, Mamawala M, Ross AE, De Marzo AM, Trock BJ, Han M, Carter HB, Lotan TL. PTEN status assessment in the Johns Hopkins active surveillance cohort. Prostate Cancer and Prostatic Diseases. PMID 30279579 DOI: 10.1038/S41391-018-0093-2  0.526
2018 Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, Sboner A, Bareja R, Esopi D, Isaacs WB, Yegnasubramanian S, Rettig MB, Elashoff DA, Platz EA, De Marzo AM, et al. CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer & Metabolism. 6: 13. PMID 30258629 DOI: 10.1186/S40170-018-0186-3  0.553
2018 Langston ME, Pakpahan R, Nevin RL, De Marzo AM, Elliott DJ, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Zenilman JM, Platz EA, Sutcliffe S. Sustained influence of infections on prostate-specific antigen concentration: An analysis of changes over 10 years of follow-up. The Prostate. 78: 1024-1034. PMID 30133756 DOI: 10.1002/Pros.23660  0.466
2018 Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL. Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. Oral Oncology. 84: 134-136. PMID 30122219 DOI: 10.1016/j.oraloncology.2018.06.026  0.406
2018 Trabzonlu L, Kulac I, Zheng Q, Hicks JL, Haffner MC, Nelson WG, Sfanos KS, Ertunc O, Lotan TL, Heaphy CM, Meeker AK, Yegnasubramanian S, De Marzo AM. Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harbor Perspectives in Medicine. PMID 30082453 DOI: 10.1101/Cshperspect.A030403  0.59
2018 DuPre NC, Flavin R, Sfanos KS, Unger RH, To S, Gazeeva E, Fiorentino M, De Marzo AM, Rider JR, Mucci LA. Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors. The Prostate. PMID 30009541 DOI: 10.1002/Pros.23692  0.453
2018 Yegnasubramanian S, De Marzo AM, Nelson WG. Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications. Cold Spring Harbor Perspectives in Medicine. PMID 29959132 DOI: 10.1101/Cshperspect.A030445  0.667
2018 Alharbi AM, De Marzo AM, Hicks JL, Lotan TL, Epstein JI. Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases. The American Journal of Surgical Pathology. PMID 29944471 DOI: 10.1097/PAS.0000000000001112  0.545
2018 Markowski MC, Hubbard GK, Hicks JL, Zheng Q, King A, Esopi D, Rege A, Yegnasubramanian S, Bieberich CJ, De Marzo AM. Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate. The Prostate. PMID 29851094 DOI: 10.1002/Pros.23657  0.679
2018 Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. The Prostate. PMID 29761525 DOI: 10.1002/Pros.23646  0.535
2018 Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan T, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, ... ... De Marzo AM, et al. Comprehensive evaluation of PD-L1 expression in primary and metastatic prostate cancer. The American Journal of Pathology. PMID 29577933 DOI: 10.1016/J.Ajpath.2018.02.014  0.365
2018 Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Clinical implications of PTEN loss in prostate cancer. Nature Reviews. Urology. PMID 29460925 DOI: 10.1038/Nrurol.2018.9  0.525
2017 Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA. Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. The Prostate. PMID 29164645 DOI: 10.1002/Pros.23462  0.574
2017 Valkenburg KC, De Marzo AM, Williams BO. Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression. Oncotarget. 8: 80265-80277. PMID 29113300 DOI: 10.18632/Oncotarget.17919  0.632
2017 Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM. The inflammatory microenvironment and microbiome in prostate cancer development. Nature Reviews. Urology. PMID 29089606 DOI: 10.1038/Nrurol.2017.167  0.647
2017 Markowski MC, De Marzo AM, Antonarakis ES. BET inhibitors in metastatic prostate cancer: Therapeutic implications and rational drug combinations. Expert Opinion On Investigational Drugs. PMID 29032717 DOI: 10.1080/13543784.2017.1393518  0.602
2017 Benedetti I, De Marzo AM, Geliebter J, Reyes N. CXXC5 expression in prostate cancer: implications for cancer progression. International Journal of Experimental Pathology. 98: 234-243. PMID 29027288 DOI: 10.1111/Iep.12241  0.664
2017 Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM. MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. The Journal of Pathology. PMID 28888037 DOI: 10.1002/Path.4980  0.73
2017 Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, Wu X, Luo Y, Su N, Nava Rodrigues D, Figueiredo I, et al. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. European Urology. PMID 28866255 DOI: 10.1016/j.eururo.2017.08.009  0.566
2017 Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS. Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. The Journal of Urology. PMID 28797714 DOI: 10.1016/J.Juro.2017.08.001  0.631
2017 Guedes L, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris SA, Hicks JL, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL. MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28790115 DOI: 10.1158/1078-0432.Ccr-17-0955  0.653
2017 Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM. A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 28754796 DOI: 10.1158/1055-9965.Epi-17-0503  0.635
2017 Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, ... ... De Marzo AM, et al. AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nature Communications. 8: 142. PMID 28747635 DOI: 10.1038/S41467-017-00084-8  0.563
2017 Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, et al. PSMA-targeted (18)F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study. The Journal of Urology. PMID 28736318 DOI: 10.1016/J.Juro.2017.07.070  0.429
2017 Milbrandt M, Winter AC, Nevin RL, Pakpahan R, Bradwin G, De Marzo AM, Elliott DJ, Gaydos CA, Isaacs WB, Nelson WG, Rifai N, Sokoll LJ, Zenilman JM, Platz EA, Sutcliffe S. Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection. The Prostate. PMID 28703328 DOI: 10.1002/Pros.23392  0.49
2017 Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, ... ... De Marzo AM, et al. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discovery. PMID 28515055 DOI: 10.1158/2159-8290.Cd-16-0960  0.658
2017 Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT. Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget. PMID 28493842 DOI: 10.18632/Oncotarget.17362  0.588
2017 Guedes L, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, Netto G, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL. Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28446506 DOI: 10.1158/1078-0432.Ccr-17-0257  0.328
2017 Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, et al. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. The Prostate. PMID 28317149 DOI: 10.1002/Pros.23346  0.497
2017 Lotan TL, Torres A, Zhang M, Tosoian JJ, Guedes LB, Fedor H, Hicks J, Ewing CM, Isaacs SD, Johng D, De Marzo AM, Isaacs WB. Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. Oncotarget. PMID 28186998 DOI: 10.18632/Oncotarget.15196  0.506
2017 Guner G, Sirajuddin P, Zheng Q, Bai B, Brodie A, Liu H, Af Hallstrom T, Kulac I, Laiho M, De Marzo AM. Novel Assay to Detect RNA Polymerase I Activity in vivo. Molecular Cancer Research : McR. PMID 28119429 DOI: 10.1158/1541-7786.Mcr-16-0246  0.545
2016 Puhr M, De Marzo A, Isaacs W, Lucia MS, Sfanos K, Yegnasubramanian S, Culig Z. Inflammation, Microbiota, and Prostate Cancer. European Urology Focus. 2: 374-382. PMID 28723469 DOI: 10.1016/J.Euf.2016.08.010  0.619
2016 Hempel HA, Cuka NS, Kulac I, Barber JR, Cornish TC, Platz EA, De Marzo AM, Sfanos KS. Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence. The Prostate. PMID 27868214 DOI: 10.1002/Pros.23280  0.625
2016 Rodrigues DN, Boysen G, Sumanasuriya S, Seed G, De Marzo AM, de Bono J. The molecular underpinnings of prostate cancer: impacts on management and pathology practice. The Journal of Pathology. PMID 27753448 DOI: 10.1002/path.4826  0.549
2016 Tosoian JJ, Almutairi F, Morais CL, Glavaris S, Hicks J, Sundi D, Humphreys E, Han M, De Marzo AM, Ross AE, Tomlins SA, Schaeffer EM, Trock BJ, Lotan TL. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. European Urology. PMID 27477529 DOI: 10.1016/J.Eururo.2016.07.026  0.362
2016 Kulac I, Gumuskaya B, Drake CG, Gonzalez B, Arnold KB, Goodman PJ, Kristal AR, Lucia MS, Thompson IM, Isaacs WB, De Marzo AM, Platz EA. Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the prostate cancer prevention trial . The Prostate. PMID 27325488 DOI: 10.1002/Pros.23224  0.485
2016 Morais CL, Guedes LB, Hicks J, Baras AS, De Marzo AM, Lotan TL. ERG and PTEN Status of Isolated High Grade PIN Occurring in Cystoprostatectomy Specimens Without Invasive Prostatic Adenocarcinoma. Human Pathology. PMID 27189342 DOI: 10.1016/j.humpath.2016.04.017  0.587
2016 Guedes L, Morais C, Almutairi F, Haffner MC, Zheng Q, Isaacs JT, Antonarakis ES, Lu C, Tsai H, Luo J, De Marzo AM, Lotan TL. Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27166397 DOI: 10.1158/1078-0432.Ccr-16-0205  0.647
2016 Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27080984 DOI: 10.1038/Modpathol.2016.63  0.351
2016 Padmanabhan A, Rao V, De Marzo AM, Bieberich CJ. Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants. The Prostate. 76: 523-33. PMID 26841725 DOI: 10.1002/Pros.23144  0.601
2016 Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG, Rasheed ZA, Hicks J, Cochran RL, Croessmann S, Zabransky DJ, Mohseni M, Beaver JA, Chu D, Cravero K, ... ... De Marzo AM, et al. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget. PMID 26823390 DOI: 10.18632/Oncotarget.7057  0.337
2016 De Marzo AM, Haffner MC, Lotan TL, Yegnasubramanian S, Nelson WG. Premalignancy in Prostate Cancer: Rethinking What we Know. Cancer Prevention Research (Philadelphia, Pa.). PMID 26813971 DOI: 10.1158/1940-6207.Capr-15-0431  0.455
2016 Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, ... ... De Marzo AM, et al. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. Journal of the National Cancer Institute. 108. PMID 26615022 DOI: 10.1093/jnci/djv346  0.634
2015 Murtola T, Gurel B, Umbehr M, Lucia MS, Thompson IM, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, et al. Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 26715424 DOI: 10.1158/1055-9965.Epi-15-0987  0.667
2015 Sutcliffe S, Nevin RL, Pakpahan R, Elliott DJ, Langston ME, De Marzo AM, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Walsh PC, Zenilman JM, Cersovsky SB, Platz EA. Infectious Mononucleosis, Other Infections, and Prostate-Specific Antigen Concentration as a Marker of Prostate Involvement During Infection. International Journal of Cancer. Journal International Du Cancer. PMID 26678984 DOI: 10.1002/Ijc.29966  0.544
2015 Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, Horn LA, Kulac I, Moubarek MS, Nelson PS, Yegnasubramanian S, De Marzo AM, Bieberich CJ. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Research. PMID 26554830 DOI: 10.1158/0008-5472.Can-14-3280  0.544
2015 Haffner MC, Weier C, Xu M, Vaghasia A, Gürel B, Gümüşkaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, ... De Marzo AM, et al. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. The Journal of Pathology. PMID 26331372 DOI: 10.1002/Path.4628  0.507
2015 Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks JL, Gupta N, Epstein JI, Netto GJ, Isaacs WB, Luo J, Mehra R, Vessella RL, Karnes RJ, Schaeffer E, ... ... De Marzo AM, et al. Cyclin D1 Loss Distinguishes Prostatic Small Cell Carcinoma from Most Prostatic Adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26246306 DOI: 10.1158/1078-0432.Ccr-15-0744  0.518
2015 Morais CL, Herawi M, Toubaji A, Albadine R, Hicks J, Netto GJ, De Marzo AM, Epstein JI, Lotan TL. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. The Prostate. 75: 1610-9. PMID 26178158 DOI: 10.1002/pros.23042  0.663
2015 Yu SH, Zheng Q, Esopi D, Macgregor-Das A, Luo J, Antonarakis ES, Drake CG, Vessella R, Morrissey C, De Marzo AM, Sfanos KS. A Paracrine Role for IL-6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. Cancer Immunology Research. PMID 26048576 DOI: 10.1158/2326-6066.Cir-15-0013  0.437
2015 Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippmann SM, Parnes HL, Dluzniewski PJ, Isaacs WB, ... De Marzo AM, et al. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. The Prostate. PMID 26047319 DOI: 10.1002/Pros.23021  0.651
2015 Sfanos KS, Canene-Adams K, Hempel H, Yu SH, Simons BW, Schaeffer AJ, Schaeffer EM, Nelson WG, De Marzo AM. Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)-Induced Cancer at Multiple Sites. Cancer Prevention Research (Philadelphia, Pa.). 8: 683-92. PMID 25990088 DOI: 10.1158/1940-6207.Capr-15-0090  0.52
2015 Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Van Blarigan EL, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA. Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. Cancer Prevention Research (Philadelphia, Pa.). 8: 737-42. PMID 25990087 DOI: 10.1158/1940-6207.Capr-15-0097  0.537
2015 Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA. Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prevention Research (Philadelphia, Pa.). 8: 590-6. PMID 25926387 DOI: 10.1158/1940-6207.Capr-14-0398  0.414
2015 Heaphy CM, Gaonkar G, Peskoe SB, Joshu CE, De Marzo AM, Lucia MS, Goodman PJ, Lippman SM, Thompson IM, Platz EA, Meeker AK. Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. The Prostate. 75: 1160-6. PMID 25893825 DOI: 10.1002/Pros.22997  0.666
2015 Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM. Should Gleason 6 be labeled as cancer? Current Opinion in Urology. 25: 238-45. PMID 25730327 DOI: 10.1097/Mou.0000000000000165  0.55
2015 Wang CC, De Marzo AM, Lotan TL, Epstein JI. Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma. Human Pathology. 46: 554-7. PMID 25656929 DOI: 10.1016/j.humpath.2014.12.007  0.477
2015 Liang J, Li Y, Daniels G, Sfanos K, De Marzo A, Wei J, Li X, Chen W, Wang J, Zhong X, Melamed J, Zhao J, Lee P. LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a. Molecular Cancer Research : McR. 13: 681-8. PMID 25587085 DOI: 10.1158/1541-7786.Mcr-14-0503  0.321
2015 Morais CL, Han JS, Gordetsky J, Nagar MS, Anderson AE, Lee S, Hicks JL, Zhou M, Magi-Galluzzi C, Shah RB, Epstein JI, De Marzo AM, Lotan TL. Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. The American Journal of Surgical Pathology. 39: 169-78. PMID 25517949 DOI: 10.1097/PAS.0000000000000348  0.354
2015 Sutcliffe S, Till C, Jenkins FJ, Gaydos CA, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Nelson WG, De Marzo AM, Platz EA. Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes & Control : Ccc. 26: 35-44. PMID 25359302 DOI: 10.1007/S10552-014-0480-5  0.649
2015 Tan HL, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, Ghosh S, Hicks JL, Zheng Q, Sangoi AR, Yegnasubramanian S, Osunkoya AO, De Marzo AM, Epstein JI, Lotan TL. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28: 446-56. PMID 25216229 DOI: 10.1038/Modpathol.2014.115  0.503
2015 Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28: 128-37. PMID 24993522 DOI: 10.1038/Modpathol.2014.85  0.49
2015 Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB. Diagnostic challenges of clonal heterogeneity in prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: e38-40. PMID 24638011 DOI: 10.1200/Jco.2013.50.3540  0.672
2014 Priolo C, Pyne S, Rose J, Regan ER, Zadra G, Photopoulos C, Cacciatore S, Schultz D, Scaglia N, McDunn J, De Marzo AM, Loda M. AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Research. 74: 7198-204. PMID 25322691 DOI: 10.1158/0008-5472.Can-14-1490  0.55
2014 Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine. 371: 1028-38. PMID 25184630 DOI: 10.1056/Nejmoa1315815  0.523
2014 Valkenburg KC, Yu X, De Marzo AM, Spiering TJ, Matusik RJ, Williams BO. Activation of Wnt/β-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasia. The Prostate. 74: 1506-20. PMID 25175604 DOI: 10.1002/Pros.22868  0.651
2014 Bhavsar NA, Bream JH, Meeker AK, Drake CG, Peskoe SB, Dabitao D, De Marzo AM, Isaacs WB, Platz EA. A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 2561-7. PMID 25150281 DOI: 10.1158/1055-9965.Epi-14-0010  0.331
2014 Mendonca J, Sharma A, Kim HS, Hammers H, Meeker A, De Marzo A, Carducci M, Kauffman M, Shacham S, Kachhap S. Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget. 5: 6102-12. PMID 25026284 DOI: 10.18632/Oncotarget.2174  0.621
2014 Sfanos KS, Hempel HA, De Marzo AM. The role of inflammation in prostate cancer. Advances in Experimental Medicine and Biology. 816: 153-81. PMID 24818723 DOI: 10.1007/978-3-0348-0837-8_7  0.632
2014 Chung CC, Hsing AW, Edward Yeboah, Biritwum R, Tettey Y, Adjei A, Cook MB, De Marzo A, Netto G, Tay E, Boland JF, Yeager M, Chanock SJ. A comprehensive resequence-analysis of 250 kb region of 8q24.21 in men of African ancestry. The Prostate. 74: 579-89. PMID 24783269 DOI: 10.1002/pros.22726  0.386
2014 Gurel B, Lucia MS, Thompson IM, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, Peskoe SB, Drake CG, Nelson WG, De Marzo AM, Platz EA. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 847-56. PMID 24748218 DOI: 10.1158/1055-9965.Epi-13-1126  0.656
2014 Hsing AW, Yeboah E, Biritwum R, Tettey Y, De Marzo AM, Adjei A, Netto GJ, Yu K, Li Y, Chokkalingam AP, Chu LW, Chia D, Partin A, Thompson IM, Quraishi SM, et al. High prevalence of screen detected prostate cancer in West Africans: implications for racial disparity of prostate cancer. The Journal of Urology. 192: 730-5. PMID 24747091 DOI: 10.1016/j.juro.2014.04.017  0.644
2014 Rodić N, Sharma R, Sharma R, Zampella J, Dai L, Taylor MS, Hruban RH, Iacobuzio-Donahue CA, Maitra A, Torbenson MS, Goggins M, Shih IeM, Duffield AS, Montgomery EA, Gabrielson E, ... ... De Marzo AM, et al. Long interspersed element-1 protein expression is a hallmark of many human cancers. The American Journal of Pathology. 184: 1280-6. PMID 24607009 DOI: 10.1016/J.Ajpath.2014.01.007  0.313
2014 Sutcliffe S, De Marzo AM, Sfanos KS, Laurence M. MSMB variation and prostate cancer risk: clues towards a possible fungal etiology. The Prostate. 74: 569-78. PMID 24464504 DOI: 10.1002/Pros.22778  0.631
2014 Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, Liu W, Isaacs WB, De Marzo AM, Lotan TL. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 890-903. PMID 24323898 DOI: 10.1158/1078-0432.Ccr-13-1982  0.616
2014 Hurwitz LM, Heaphy CM, Joshu CE, Isaacs WB, Konishi Y, De Marzo AM, Isaacs SD, Wiley KE, Platz EA, Meeker AK. Telomere length as a risk factor for hereditary prostate cancer. The Prostate. 74: 359-64. PMID 24285042 DOI: 10.1002/Pros.22755  0.632
2014 Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, Netto GJ, Trock BJ, De Marzo AM, Sfanos KS. Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. The Prostate. 74: 61-9. PMID 24115205 DOI: 10.1002/Pros.22730  0.645
2013 Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. American Journal of Clinical and Experimental Urology. 1: 3-11. PMID 25110720  0.646
2013 Canene-Adams K, Sfanos KS, Liang CT, Yegnasubramanian S, Nelson WG, Brayton C, De Marzo AM. Dietary chemoprevention of PhIP induced carcinogenesis in male Fischer 344 rats with tomato and broccoli. Plos One. 8: e79842. PMID 24312188 DOI: 10.1371/Journal.Pone.0079842  0.307
2013 Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, et al. Tracking the clonal origin of lethal prostate cancer. The Journal of Clinical Investigation. 123: 4918-22. PMID 24135135 DOI: 10.1172/Jci70354  0.639
2013 Wada S, Harris TJ, Tryggestad E, Yoshimura K, Zeng J, Yen HR, Getnet D, Grosso JF, Bruno TC, De Marzo AM, Netto GJ, Pardoll DM, DeWeese TL, Wong J, Drake CG. Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. International Journal of Radiation Oncology, Biology, Physics. 87: 769-76. PMID 24064321 DOI: 10.1016/J.Ijrobp.2013.07.015  0.573
2013 Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, Mucci LA, Kenfield SA, Stampfer MJ, Hicks JL, De Marzo AM, Platz EA, Meeker AK. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discovery. 3: 1130-41. PMID 23779129 DOI: 10.1158/2159-8290.Cd-13-0135  0.632
2013 Weier C, Haffner MC, Mosbruger T, Esopi DM, Hicks J, Zheng Q, Fedor H, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. The Journal of Pathology. 230: 174-83. PMID 23447416 DOI: 10.1002/Path.4186  0.572
2013 Shinohara DB, Vaghasia AM, Yu SH, Mak TN, Brüggemann H, Nelson WG, De Marzo AM, Yegnasubramanian S, Sfanos KS. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. The Prostate. 73: 1007-15. PMID 23389852 DOI: 10.1002/Pros.22648  0.637
2013 Lotan TL, Gumuskaya B, Rahimi H, Hicks JL, Iwata T, Robinson BD, Epstein JI, De Marzo AM. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 26: 587-603. PMID 23222491 DOI: 10.1038/modpathol.2012.201  0.376
2013 Mak TN, Yu SH, De Marzo AM, Brüggemann H, Sfanos KS. Multilocus sequence typing (MLST) analysis of Propionibacterium acnes isolates from radical prostatectomy specimens. The Prostate. 73: 770-7. PMID 23184509 DOI: 10.1002/Pros.22621  0.412
2012 Sutcliffe S, Till C, Gaydos CA, Jenkins FJ, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Zenilman JM, Nelson WG, De Marzo AM, Platz EA. Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Causes & Control : Ccc. 23: 1511-8. PMID 22810146 DOI: 10.1007/S10552-012-0028-5  0.569
2012 Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, Yegnasubramanian S, De Marzo AM. Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. The American Journal of Pathology. 181: 560-9. PMID 22713676 DOI: 10.1016/J.Ajpath.2012.04.021  0.577
2012 Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA, Netto GJ. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 1543-9. PMID 22684219 DOI: 10.1038/modpathol.2012.104  0.641
2012 Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy Cancer. 118: 6063-6071. PMID 22674438 DOI: 10.1002/cncr.27689  0.529
2012 Nelson WG, De Marzo AM, Yegnasubramanian S. USP2a activation of MYC in prostate cancer. Cancer Discovery. 2: 206-7. PMID 22585990 DOI: 10.1158/2159-8290.Cd-12-0027  0.625
2012 Toubaji A, Sutcliffe S, Chaux A, Lecksell K, Hicks J, De Marzo AM, Platz EA, Netto GJ. Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases. Human Pathology. 43: 1852-65. PMID 22554381 DOI: 10.1016/J.Humpath.2012.01.007  0.511
2012 Dunn TA, Fedor HL, De Marzo AM, Luo J. Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data. Asian Journal of Andrology. 14: 385-92. PMID 22306912 DOI: 10.1038/aja.2011.147  0.687
2012 Sfanos KS, Aloia AL, De Marzo AM, Rein A. XMRV and prostate cancer--a 'final' perspective. Nature Reviews. Urology. 9: 111-8. PMID 22231291 DOI: 10.1038/Nrurol.2011.225  0.683
2012 Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 60: 199-215. PMID 22212087 DOI: 10.1111/J.1365-2559.2011.04033.X  0.596
2011 Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 9: S1-32; quiz S33. PMID 22138009 DOI: 10.6004/Jnccn.2011.0137  0.309
2011 Ji H, Wu G, Zhan X, Nolan A, Koh C, de Marzo A, Doan HM, Fan J, Cheadle C, Fallahi M, Cleveland JL, Dang CV, Zeller KI. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation Plos One. 6. PMID 22039435 DOI: 10.1371/Journal.Pone.0026057  0.329
2011 Ghosh S, Lau H, Simons BW, Powell JD, Meyers DJ, De Marzo AM, Berman DM, Lotan TL. PI3K/mTOR signaling regulates prostatic branching morphogenesis. Developmental Biology. 360: 329-42. PMID 22015718 DOI: 10.1016/J.Ydbio.2011.09.027  0.539
2011 Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2: 669-83. PMID 21941025 DOI: 10.18632/Oncotarget.327  0.57
2011 Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IeM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, ... ... De Marzo AM, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. The American Journal of Pathology. 179: 1608-15. PMID 21888887 DOI: 10.1016/J.Ajpath.2011.06.018  0.331
2011 Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6563-73. PMID 21878536 DOI: 10.1158/1078-0432.Ccr-11-1244  0.536
2011 Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, Netto GJ. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 24: 1511-20. PMID 21743434 DOI: 10.1038/Modpathol.2011.111  0.457
2011 Sfanos KS, Aloia AL, Hicks JL, Esopi DM, Steranka JP, Shao W, Sanchez-Martinez S, Yegnasubramanian S, Burns KH, Rein A, de Marzo AM. Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines Plos One. 6. PMID 21698104 DOI: 10.1371/Journal.Pone.0020874  0.469
2011 Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. The American Journal of Surgical Pathology. 35: 1014-20. PMID 21677539 DOI: 10.1097/PAS.0b013e31821e8761  0.312
2011 Yegnasubramanian S, Wu Z, Haffner MC, Esopi D, Aryee MJ, Badrinath R, He TL, Morgan JD, Carvalho B, Zheng Q, De Marzo AM, Irizarry RA, Nelson WG. Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences. Bmc Genomics. 12: 313. PMID 21669002 DOI: 10.1186/1471-2164-12-313  0.317
2011 Koh CM, Gurel B, Sutcliffe S, Aryee MJ, Schultz D, Iwata T, Uemura M, Zeller KI, Anele U, Zheng Q, Hicks JL, Nelson WG, Dang CV, Yegnasubramanian S, De Marzo AM. Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. The American Journal of Pathology. 178: 1824-34. PMID 21435462 DOI: 10.1016/J.Ajpath.2010.12.040  0.687
2011 Haffner MC, De Marzo AM, Meeker AK, Nelson WG, Yegnasubramanian S. Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3858-64. PMID 21385925 DOI: 10.1158/1078-0432.Ccr-10-2044  0.446
2011 Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, Netto GJ. ERG gene rearrangements are common in prostatic small cell carcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 24: 820-8. PMID 21336263 DOI: 10.1038/Modpathol.2011.7  0.534
2011 Baydar DE, Kulac I, Gurel B, De Marzo A. A case of prostatic adenocarcinoma with aberrant p63 expression: Presentation with detailed immunohistochemical study and FISH analysis International Journal of Surgical Pathology. 19: 131-136. PMID 20719821 DOI: 10.1177/1066896910379478  0.542
2010 Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and Prostate Cancer. Genes & Cancer. 1: 617-28. PMID 21779461 DOI: 10.1177/1947601910379132  0.681
2010 De Marzo AM, Nelson WG, Bieberich CJ, Yegnasubramanian S. Prostate cancer: New answers prompt new questions regarding cell of origin. Nature Reviews. Urology. 7: 650-2. PMID 21139640 DOI: 10.1038/Nrurol.2010.188  0.653
2010 Jäämaa S, Af Hällström TM, Sankila A, Rantanen V, Koistinen H, Stenman UH, Zhang Z, Yang Z, De Marzo AM, Taari K, Ruutu M, Andersson LC, Laiho M. DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Research. 70: 8630-41. PMID 20978201 DOI: 10.1158/0008-5472.CAN-10-0937  0.375
2010 Aloia AL, Sfanos KS, Isaacs WB, Zheng Q, Maldarelli F, De Marzo AM, Rein A. XMRV: a new virus in prostate cancer? Cancer Research. 70: 10028-33. PMID 20966126 DOI: 10.1158/0008-5472.Can-10-2837  0.401
2010 Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature Genetics. 42: 668-75. PMID 20601956 DOI: 10.1038/Ng.613  0.598
2010 Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM. NKX3.1 as a marker of prostatic origin in metastatic tumors. The American Journal of Surgical Pathology. 34: 1097-105. PMID 20588175 DOI: 10.1097/Pas.0B013E3181E6Cbf3  0.635
2010 Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, ... ... De Marzo AM, et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3057-66. PMID 20501622 DOI: 10.1158/1078-0432.Ccr-10-0124  0.564
2010 Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, Bieberich CJ. Loss of Nkx3.1 expression in bacterial prostatitis: A potential link between inflammation and neoplasia American Journal of Pathology. 176: 2259-2268. PMID 20363913 DOI: 10.2353/Ajpath.2010.080747  0.624
2010 Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, Lotz MT, Yegnasubramanian S, Nelson WG, Dang CV, Xu M, Anele U, Koh CM, Bieberich CJ, ... De Marzo AM, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. Plos One. 5: e9427. PMID 20195545 DOI: 10.1371/Journal.Pone.0009427  0.543
2010 Sutcliffe S, Viscidi RP, Till C, Goodman PJ, Hoque AM, Hsing AW, Thompson IM, Zenilman JM, De Marzo AM, Platz EA. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 614-8. PMID 20142255 DOI: 10.1158/1055-9965.Epi-09-1080  0.519
2010 Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes & Control : Ccc. 21: 671-8. PMID 20072809 DOI: 10.1007/S10552-009-9494-9  0.488
2010 Hill KM, Kalifa S, Das JR, Bhatti T, Gay M, Williams D, Taliferro-Smith L, De Marzo AM. The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells. The Prostate. 70: 755-64. PMID 20058239 DOI: 10.1002/Pros.21108  0.545
2010 Williams SA, Xu Y, De Marzo AM, Isaacs JT, Denmeade SR. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. The Prostate. 70: 788-96. PMID 20058238 DOI: 10.1002/Pros.21111  0.608
2009 Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA. Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men with Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers Journal of Clinical Oncology. 27: 4986-4993. PMID 19720908 DOI: 10.1200/Jco.2009.21.9410  0.574
2009 Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. The Prostate. 69: 1694-703. PMID 19670224 DOI: 10.1002/Pros.21020  0.393
2009 Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Current Opinion in Pharmacology. 9: 419-26. PMID 19574101 DOI: 10.1016/J.Coph.2009.06.002  0.627
2009 Vander Griend DJ, Konishi Y, De Marzo AM, Isaacs JT, Meeker AK. Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts. The Prostate. 69: 1557-64. PMID 19562732 DOI: 10.1002/Pros.21001  0.314
2009 Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology. 150: 3991-4002. PMID 19520778 DOI: 10.1210/En.2009-0573  0.659
2009 Fujita K, Pavlovich CP, Netto GJ, Konishi Y, Isaacs WB, Ali S, De Marzo A, Meeker AK. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. Human Pathology. 40: 924-33. PMID 19368959 DOI: 10.1016/J.Humpath.2009.01.004  0.657
2009 Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II Prostate. 69: 874-885. PMID 19267370 DOI: 10.1002/Pros.20933  0.399
2009 Sfanos KS, Wilson BA, De Marzo AM, Isaacs WB. Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 3443-8. PMID 19202053 DOI: 10.1073/Pnas.0810473106  0.57
2009 Parsons JK, Saria EA, Nakayama M, Vessella RL, Sawyers CL, Isaacs WB, Faith DA, Bova GS, Samathanam CA, Mitchell R, De Marzo AM. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. The Prostate. 69: 559-69. PMID 19142959 DOI: 10.1002/Pros.20904  0.649
2009 Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. The Prostate. 69: 603-9. PMID 19125417 DOI: 10.1002/Pros.20910  0.547
2009 Sutcliffe S, Alderete JF, Till C, Goodman PJ, Hsing AW, Zenilman JM, De Marzo AM, Platz EA. Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. International Journal of Cancer. Journal International Du Cancer. 124: 2082-7. PMID 19117055 DOI: 10.1002/Ijc.24144  0.655
2009 Dunn TA, Fedor H, Isaacs WB, De Marzo AM, Luo J. Genome-wide expression analysis of recently processed formalin-fixed paraffin embedded human prostate tissues. The Prostate. 69: 214-8. PMID 18973134 DOI: 10.1002/Pros.20863  0.48
2008 Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Research. 68: 8954-67. PMID 18974140 DOI: 10.1158/0008-5472.Can-07-6088  0.66
2008 Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets Advances in Anatomic Pathology. 15: 319-331. PMID 18948763 DOI: 10.1097/Pap.0B013E31818A5C19  0.661
2008 Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 21: 1156-67. PMID 18567993 DOI: 10.1038/Modpathol.2008.111  0.607
2008 Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J. GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. The Prostate. 68: 1387-95. PMID 18543251 DOI: 10.1002/Pros.20806  0.594
2008 Fujita K, Ewing CM, Sokoll LJ, Elliott DJ, Cunningham M, De Marzo AM, Isaacs WB, Pavlovich CP. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. The Prostate. 68: 872-82. PMID 18361406 DOI: 10.1002/Pros.20755  0.656
2008 Goodwin AC, Jadallah S, Toubaji A, Lecksell K, Hicks JL, Kowalski J, Bova GS, De Marzo AM, Netto GJ, Casero RA. Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. The Prostate. 68: 766-72. PMID 18302221 DOI: 10.1002/pros.20735  0.581
2008 Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, Isaacs WB. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. The Prostate. 68: 306-20. PMID 18163428 DOI: 10.1002/Pros.20680  0.615
2007 De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urologic Oncology. 25: 398-400. PMID 17826659 DOI: 10.1016/J.UROLONC.2007.05.007  0.585
2007 Sutcliffe S, Giovannucci E, Gaydos CA, Viscidi RP, Jenkins FJ, Zenilman JM, Jacobson LP, De Marzo AM, Willett WC, Platz EA. Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 1573-80. PMID 17684131 DOI: 10.1158/1055-9965.Epi-07-0134  0.474
2007 Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. The American Journal of Surgical Pathology. 31: 882-8. PMID 17527075 DOI: 10.1097/01.pas.0000213424.38503.aa  0.631
2007 Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM. Abnormal DNA methylation, epigenetics, and prostate cancer. Frontiers in Bioscience : a Journal and Virtual Library. 12: 4254-66. PMID 17485372 DOI: 10.2741/2385  0.629
2007 De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nature Reviews. Cancer. 7: 256-69. PMID 17384581 DOI: 10.1038/Nrc2090  0.536
2007 Nakai Y, Nelson WG, De Marzo AM. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Research. 67: 1378-84. PMID 17264317 DOI: 10.1158/0008-5472.CAN-06-1336  0.621
2006 Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA. Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 2160-6. PMID 17119041 DOI: 10.1158/1055-9965.Epi-05-0913  0.644
2006 Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Research. 66: 10683-90. PMID 17108105 DOI: 10.1158/0008-5472.Can-06-0963  0.519
2006 Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J. A novel role of myosin VI in human prostate cancer. The American Journal of Pathology. 169: 1843-54. PMID 17071605 DOI: 10.2353/Ajpath.2006.060316  0.66
2006 Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 103: 15085-90. PMID 17015840 DOI: 10.1073/Pnas.0603057103  0.625
2006 De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Farree X, Fine SW, Iczkowski KA, Ittmann M, et al. A working group classification of focal prostate atrophy lesions. The American Journal of Surgical Pathology. 30: 1281-91. PMID 17001160 DOI: 10.1097/01.Pas.0000213289.50660.Be  0.491
2006 Herawi M, De Marzo AM, Kristiansen G, Epstein JI. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate. Human Pathology. 38: 72-8. PMID 16949907 DOI: 10.1016/j.humpath.2006.06.015  0.545
2006 Sutcliffe S, Giovannucci E, Alderete JF, Chang TH, Gaydos CA, Zenilman JM, De Marzo AM, Willett WC, Platz EA. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 939-45. PMID 16702374 DOI: 10.1158/1055-9965.Epi-05-0781  0.625
2006 Sutcliffe S, Zenilman JM, Ghanem KG, Jadack RA, Sokoll LJ, Elliott DJ, Nelson WG, De Marzo AM, Cole SR, Isaacs WB, Platz EA. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. The Journal of Urology. 175: 1937-42. PMID 16600802 DOI: 10.1016/S0022-5347(05)00892-X  0.483
2005 Dalrymple S, Antony L, Xu Y, Uzgare AR, Arnold JT, Savaugeot J, Sokoll LJ, De Marzo AM, Isaacs JT. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Research. 65: 9269-79. PMID 16230388 DOI: 10.1158/0008-5472.Can-04-3989  0.352
2005 Sutcliffe S, Giovannucci E, De Marzo AM, Willett WC, Platz EA. Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. American Journal of Epidemiology. 162: 898-906. PMID 16177142 DOI: 10.1093/Aje/Kwi299  0.449
2005 Faith D, Han S, Lee DK, Friedl A, Hicks JL, De Marzo AM, Jarrard DF. p16 is upregulated in proliferative inflammatory atrophy of the prostate Prostate. 65: 73-82. PMID 15880529 DOI: 10.1002/Pros.20258  0.64
2005 Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 390-6. PMID 15734963 DOI: 10.1158/1055-9965.Epi-04-0532  0.54
2005 Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, Luo J, De Marzo AM, Isaacs WB. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. The Prostate. 63: 316-23. PMID 15599942 DOI: 10.1002/Pros.20177  0.5
2005 Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 26: 1170-81. PMID 15498784 DOI: 10.1093/Carcin/Bgh317  0.679
2004 Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. European Urology. 46: 698-708. PMID 15548435 DOI: 10.1016/J.Eururo.2004.07.022  0.62
2004 Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. The Journal of Urology. 172: S6-11; discussion S1. PMID 15535435 DOI: 10.1097/01.Ju.0000142058.99614.Ff  0.68
2004 Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Letters. 215: 1-20. PMID 15374627 DOI: 10.1016/J.Canlet.2004.06.014  0.394
2004 Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AM, Nelson WG, Pavlovich CP. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein. The Journal of Urology. 172: 1501-3. PMID 15371879 DOI: 10.1097/01.Ju.0000137659.53129.14  0.596
2004 Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, De Marzo AM. Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays Prostate. 61: 215-227. PMID 15368473 DOI: 10.1002/Pros.20095  0.561
2004 Meeker AK, Hicks JL, Iacobuzio-Donahue CA, Montgomery EA, Westra WH, Chan TY, Ronnett BM, De Marzo AM. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3317-26. PMID 15161685 DOI: 10.1158/1078-0432.Ccr-0984-03  0.413
2004 Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detection and Prevention. 28: 88-93. PMID 15068831 DOI: 10.1016/J.Cdp.2003.12.009  0.592
2004 Platz EA, De Marzo AM, Erlinger TP, Rifai N, Visvanathan K, Hoffman SC, Helzlsouer KJ. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. The Prostate. 59: 393-400. PMID 15065087 DOI: 10.1002/Pros.10368  0.515
2004 Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Research. 64: 1975-86. PMID 15026333 DOI: 10.1158/0008-5472.Can-03-3972  0.683
2004 Gonzalgo ML, Nakayama M, Lee SM, De Marzo AM, Nelson WG. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology. 63: 414-8. PMID 14972513 DOI: 10.1016/j.urology.2003.08.039  0.515
2004 Platz EA, De Marzo AM, Giovannucci E. Failure to detect prostate cancer in the PSA era: Comments on N Engl J Med 2003; 349: 215-224 and N Engl J Med 2003; 349: 335-342 Cancer Causes and Control. 15: 91-94. PMID 14970739 DOI: 10.1023/B:Caco.0000016580.49577.09  0.491
2004 Platz EA, De Marzo AM, Giovannucci E. Prostate cancer association studies: Pitfalls and solutions to cancer misclassification in the PSA era Journal of Cellular Biochemistry. 91: 553-571. PMID 14755685 DOI: 10.1002/Jcb.10700  0.649
2004 Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. Journal of Cellular Biochemistry. 91: 540-52. PMID 14755684 DOI: 10.1002/Jcb.10740  0.639
2004 De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. Journal of Cellular Biochemistry. 91: 459-77. PMID 14755677 DOI: 10.1002/Jcb.10747  0.652
2004 Rubin MA, De Marzo AM. Molecular genetics of human prostate cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 17: 380-8. PMID 14752525 DOI: 10.1038/modpathol.3800051  0.667
2004 Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer Journal of Urology. 171. PMID 14713751 DOI: 10.1097/01.ju.0000108131.43160.77  0.602
2004 Meeker AK, De Marzo AM. Recent advances in telomere biology: implications for human cancer. Current Opinion in Oncology. 16: 32-8. PMID 14685090 DOI: 10.1097/00001622-200401000-00007  0.353
2004 Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, Yeo CJ, Hruban RH. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 16: 902-12. PMID 13679454 DOI: 10.1097/01.MP.0000086072.56290.FB  0.351
2003 Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Research. 63: 7365-76. PMID 14612535  0.513
2003 De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG. Human prostate cancer precursors and pathobiology. Urology. 62: 55-62. PMID 14607218 DOI: 10.1016/J.Urology.2003.09.053  0.684
2003 Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM. Hypermethylation of the human glutathione S-transferase-π gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: A detailed study using laser-capture microdissection American Journal of Pathology. 163: 923-933. PMID 12937133 DOI: 10.1016/S0002-9440(10)63452-9  0.44
2003 Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, De Marzo AM, Epstein JI. α-methylacyl-CoA racemase: A variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy American Journal of Surgical Pathology. 27: 1128-1133. PMID 12883245 DOI: 10.1097/00000478-200308000-00010  0.593
2003 Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. The New England Journal of Medicine. 349: 366-81. PMID 12878745 DOI: 10.1056/NEJMra021562  0.686
2003 Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? The Journal of Clinical Endocrinology and Metabolism. 88: 2972-82. PMID 12843129 DOI: 10.1210/Jc.2002-022038  0.634
2003 Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell. 2: 113-6. PMID 12204531 DOI: 10.1016/S1535-6108(02)00103-4  0.645
2002 Heath EI, DeWeese TL, Partin AW, De Marzo AM, Groopman JD, Nelson WG, Piantadosi SA, Lieberman R, Carducci MA. The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate. Clinical Prostate Cancer. 1: 182-7. PMID 15046694 DOI: 10.3816/Cgc.2002.N.021  0.409
2002 Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, De Marzo AM. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Research. 62: 6405-9. PMID 12438224  0.484
2002 Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3419-26. PMID 12429629  0.503
2002 De Marzo AM, Fedor HH, Gage WR, Rubin MA. Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays. Human Pathology. 33: 756-60. PMID 12196928 DOI: 10.1053/hupa.2002.126187  0.303
2002 Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Research. 62: 2220-6. PMID 11956072  0.693
Show low-probability matches.